Welcome!

News Feed Item

Skystar Bio-Pharmaceutical Announces Results for Third Quarter Fiscal Year 2012

Veterinary Medication Facility Resumes Production and Distribution; Veterinary Vaccine Facility Receives Initial GMP Certification

XI'AN, CHINA -- (Marketwire) -- 11/15/12 -- Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) ("Skystar" or the "Company"), a China-based manufacturer and distributor of veterinary medicines, vaccines, micro-organisms and feed additives, today reported unaudited third quarter fiscal year 2012 earnings, for the period ended September 30, 2012.

Third Quarter 2012 Highlights

  • Revenue decrease 57% YoY to $8.9 million
    • Veterinary vaccines totaled $1.0 million, up 19% YoY
    • Veterinary medicines totaled $1.8 million, down 86% YoY
    • Feed additives totaled $1.2 million, up 13% YoY
    • Probiotics products totaled $4.9 million, down 18% YoY
  • Gross margin of 59% for the third quarter of fiscal 2011 as compared to 52% in the year ago period
  • GAAP net income declined 65% to $2.7 million or $0.36 per fully diluted share, compared with net income of $7.7 million or $1.08 per fully diluted share in the year ago period
  • Fiscal 2012 top line revenue guidance range revised from $33 million to $38 million reflecting inactivity of the veterinary medications facility due to timing of its GMP re-certification process.

Nine Month 2012 Highlights

  • Net revenue declined 31% YoY to $25.7 million
  • Gross profit of $14.7 million for the nine months of fiscal 2012 as compared to $18.9 million in the year ago period
  • GAAP net income $6.3 million, compared with GAAP net income of $11.2 million in the year ago period

Mr. Weibing Lu, Skystar Bio-Pharmaceutical's Chairman and Chief Executive Officer, commented, "Skystar has made significant strides in moving its infrastructure forward in support of manufacturing capacity for the Company's veterinary medication and vaccine lines providing a solid outlook in the medium and long term.

"Skystar has resumed production and distribution of its primary veterinary medicine following GMP recertification by the Ministry of Agriculture. In addition, Skystar's animal and aquaculture vaccine production facility passed initial GMP certification, and, when it operates and reaches its full production levels, is expected to generate at minimum $15 million in annual sales.

"Once operational, the much anticipated vaccine facility will allow Skystar to mass produce vaccines currently produced by hand in large quality controlled batches. Both the certification of the veterinary medicine and vaccine plants are significant milestones for Skystar and are vital in supporting the Company's growth in upcoming years."

Mr. Lu concluded, "In terms of Skystar's performance for the 3rd quarter of 2012, it is noteworthy that, in spite of China's 'soft' economic performance which is partly attributable to fiscal policies designed to control inflation, Skystar has been able to maintain and, at times, marginally increase sales pricing for its products. With this in mind, Skystar's 3rd quarter revenue and bottom line largely reflect a revenue drop in its veterinary medication business in the 3rd quarter, which accounts for nearly 60% of Skystar's revenues in any given period. This is a short term effect related to the closure of Skystar's veterinary medication facility during the pendency of the GMP recertification process. Now that Skystar has resumed production at this facility, Skystar can continue its commitment to maintaining bottom line profitability in its organic business in order to fund growth and expansion initiatives internally for years to come."

Forecast
With the loss of revenue from the veterinary medication plant for all of the third quarter, Skystar's seasonally strongest quarter, the Company is recasting guidance to be in the range of $33 million to $38 million for fiscal 2012.

Financial Summary
Revenues for third quarter 2012, decreased 57% to $8.9 million as compared to $20.9 million in the year ago period.

Gross profit third quarter 2012 was roughly $5.3 million, down 52% from third quarter 2011.

Gross margin for the period was higher at 59% compared to 52% in the year ago period, due to the change in available product mix for sale.

Total operating expenses for third quarter 2012 was $1.6 million, or 18% of total revenue, compared with $1.9 million or 9% of total revenue in the year ago period.

Research and development costs totaled roughly $200,000 for the period, as compared to roughly $91,000 for the three months ended September 30, 2011, an increase of 118%.

Selling expenses totaled $690,000 for third quarter 2012 as compared to $1.2 million for the comparable year ago period this was a decrease of roughly $480,000 or 41%.

General and administrative expenses totaled $730,000 in the third quarter of 2012 as compared to $602,000 for the year ago period, an increase of $128,000 or 21%.

Operating income decreased 59% year over year and was $3.6 million in the third quarter of fiscal 2012 as compared to $9.0 million in the year ago period, operating margin remained level at 41% as compared to 43% from the year ago period.

Net income for the third quarter of 2012 was $2.7 million, or $0.36 per fully diluted share. This compares to net income of $7.7 million or $1.08 per fully diluted share in the same quarter of 2011.

As of September 30, 2012, Skystar had approximately $2.7 million in cash and current assets of $73 million and current liabilities of $20 million.

Conference Call & Webcast Information
The Company will host a conference call on Thursday, November 15, 2012 to discuss the quarter. Skystar's conference call will begin promptly at 7:45 a.m. ET to discuss third quarter financial results and operational performance. Mr. Weibing Lu, Skystar's chairman and chief executive officer, will host the call, which will be webcast live.

Webcast
The webcast will be made available on the investor relations section of the Skystar corporate website at http://www.investorcalendar.com/IC/CEPage.asp?ID=170249.

Phone dial-in
Telephone access to the conference call will be available in North America by dialing +1 (877) 407-8031 or internationally by dialing +1 (201) 689-8031.

An audio replay of the conference call will be available approximately two hours following the conclusion of the call and for the following 30 day period. To access the replay in North America, dial +1 (877) 660-6853 or, when calling internationally, dial +1 (201) 612-7415, using conference ID # 398886. An archived replay of the conference webcast will also be available on investor relations section of the Skystar corporate website at http://www.skystarbio-pharmaceutical.com.

To be added to the Company's email distribution for future news releases, please send your request to [email protected].

About Skystar Bio-Pharmaceutical Company
Skystar is a China-based developer and distributor of veterinary healthcare and medical care products. Skystar has four product lines (veterinary medicines, micro-organisms, vaccines and feed additives) and over 284 products. Skystar has formed strategic sales distribution networks covering 29 provinces throughout China. For additional information, please visit http://www.skystarbio-pharmaceutical.com.



            SKYSTAR BIO-PHARMACEUTICAL COMPANY AND SUBSIDIARIES
    CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME
   FOR THE THREE MONTHS AND NINE MONTHS ENDED SEPTEMBER 30, 2012 AND 2011
                                (Unaudited)

                            For Three Months Ended   For Nine Months Ended
                                September 30,            September 30,
                           ----------------------- ------------------------
                              2012         2011        2012         2011
                           ----------  ----------- -----------  -----------

REVENUE, NET               $8,933,005  $20,903,063 $25,730,190  $37,086,158

COST OF REVENUE             3,670,230   10,057,212  11,060,826   18,185,565
                           ----------  ----------- -----------  -----------

GROSS PROFIT                5,262,775   10,845,851  14,669,364   18,900,593
                           ----------  ----------- -----------  -----------

OPERATING EXPENSES:
Research and development
 costs                        198,838       91,124     533,024    2,180,147
Selling expenses              692,009    1,174,928   2,068,192    2,154,158
General and administrative
 expenses                     730,539      602,248   3,670,254    2,412,339
                           ----------  ----------- -----------  -----------
Total operating expenses    1,621,386    1,868,300   6,271,470    6,746,644
                           ----------  ----------- -----------  -----------

INCOME FROM OPERATIONS      3,641,389    8,977,551   8,397,894   12,153,949
                           ----------  ----------- -----------  -----------

OTHER INCOME (EXPENSE):
Other income (expense),
 net                             (734)       9,421      55,264        5,054
Interest income (expense),
 net                         (199,238)      15,036    (378,779)     (54,265)
Change in fair value of
 warrant/purchase option
 liability                      7,000      171,765      29,400    1,267,412
                           ----------  ----------- -----------  -----------
Total other income
 (expense), net              (192,972)     196,222    (294,115)   1,218,201
                           ----------  ----------- -----------  -----------

INCOME BEFORE PROVISION
 FOR INCOME TAXES           3,448,417    9,173,773   8,103,779   13,372,150

PROVISION FOR INCOME TAXES    717,163    1,446,112   1,768,905    2,205,267
                           ----------  ----------- -----------  -----------

NET INCOME                  2,731,254    7,727,661   6,334,874   11,166,883

OTHER COMPREHENSIVE INCOME
Foreign currency
 translation adjustment      (198,269)     898,786     484,203    2,494,959
                           ----------  ----------- -----------  -----------

COMPREHENSIVE INCOME       $2,532,985  $ 8,626,447 $ 6,819,077  $13,661,842
                           ==========  =========== ===========  ===========

EARNINGS PER SHARE:
Basic                      $     0.36  $      1.08 $      0.85  $      1.56
                           ==========  =========== ===========  ===========
Diluted                    $     0.36  $      1.08 $      0.85  $      1.56
                           ==========  =========== ===========  ===========

WEIGHTED AVERAGE NUMBER OF
 COMMON SHARES:
Basic                       7,604,800    7,172,354   7,426,082    7,171,530
                           ==========  =========== ===========  ===========
Diluted                     7,604,800    7,172,354   7,426,082    7,174,668
                           ==========  =========== ===========  ===========





             SKYSTAR BIO-PHARMACEUTICAL COMPANY AND SUBSIDIARIES
                    CONDENSED CONSOLIDATED BALANCE SHEETS

                                                September 30,  December 31,
                                                    2012           2011
                                                 (Unaudited)
                    ASSETS
CURRENT ASSETS:
  Cash                                         $    2,668,532 $    7,048,968
  Accounts receivable, net of allowance for
   doubtful accounts of $472,483 and $438,678
   as of September 30, 2012 and December 31,
   2011, respectively                              15,457,752      3,391,493
  Inventories                                      15,272,511     14,851,159
  Deposits, prepaid expenses and other
   receivables                                      3,139,404      3,421,487
  Prepayments to suppliers                         34,834,548     29,226,961
  Loans receivable                                  2,106,998        964,088
                                               -------------- --------------
    Total current assets                           73,479,745     58,904,156
                                               -------------- --------------

PROPERTY, PLANT AND EQUIPMENT, NET                 28,904,306     28,376,559

CONSTRUCTION-IN-PROGRESS                            8,686,322      8,839,055

OTHER ASSETS:
  Long-term prepayments                             1,033,875      1,512,817
  Long-term prepayments for acquisitions              177,296        569,788
  Intangible assets, net                            5,406,479      5,674,206
                                               -------------- --------------
    Total other assets                              6,617,650      7,756,811
                                               -------------- --------------
      Total assets                             $  117,688,023 $  103,876,581
                                               ============== ==============

     LIABILITIES AND SHAREHOLDERS' EQUITY

CURRENT LIABILITIES:
  Accounts payable                             $    4,123,218 $    1,047,067
  Other payables and accrued expenses               3,575,584      5,274,598
  Short-term loans                                  9,181,400      7,366,320
  Deposits from customers                           1,347,993      1,432,529
  Taxes payable                                     1,238,105        160,081
  Due to related parties                              386,533         56,273
                                               -------------- --------------
    Total current liabilities                      19,852,833     15,336,868
                                               -------------- --------------

OTHER LIABILITIES:
  Long-term loan                                    1,266,400              -
  Deferred government grant                           395,750        393,500
  Warrant/purchase option liability                    14,000         43,400
                                               -------------- --------------
    Total other liabilities                         1,676,150        436,900
                                               -------------- --------------
      Total liabilities                            21,528,983     15,773,768
                                               -------------- --------------

COMMITMENTS AND CONTINGENCIES

SHAREHOLDERS' EQUITY
  Preferred stock, $0.001 par value,
   50,000,000 shares authorized. No Series "A"
   shares authorized. 48,000,000 Series "B"
   shares authorized. No Series "B" shares
   issued and outstanding                                   -              -
  Common stock, $0.001 par value, 40,000,000
   shares authorized, 7,604,800 and 7,161,919
   shares issued and outstanding as of
   September 30, 2012 (Unaudited) and December
   31, 2011, respectively                               7,605          7,162
  Paid-in capital                                  37,021,085     35,784,378
  Statutory reserves                                5,708,135      5,708,135
  Retained earnings                                44,826,905     38,492,031
  Accumulated other comprehensive income            8,595,310      8,111,107
                                               -------------- --------------
    Total shareholders' equity                     96,159,040     88,102,813
                                               -------------- --------------
      Total liabilities and shareholders'
       equity                                  $  117,688,023 $  103,876,581
                                               ============== ==============



            SKYSTAR BIO-PHARMACEUTICAL COMPANY AND SUBSIDIARIES
              CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
           FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2012 AND 2011
                                (Unaudited)

                                                     Nine months ended
                                                       September 30,
                                                     2012          2011
                                                ------------- -------------
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income                                      $   6,334,874 $  11,166,883
Adjustments to reconcile net income to net cash
 provided by (used in) operating activities:
  Depreciation                                        920,444       709,749
  Amortization                                        300,589       432,098
  Provision for doubtful accounts                      31,340
  Change in fair value of warrant/purchase
   option liability                                   (29,400)   (1,267,412)
  Common stock to be issued to related parties
   for compensation                                                  72,965
  Common stock issued under 2010 stock
   incentive plan                                   1,037,911
Change in operating assets and liabilities
  Accounts receivable                             (12,094,949)   (4,566,868)
  Inventories                                        (336,902)   (6,890,055)
  Deposits, prepaid expenses and other
   receivables                                        404,130       151,534
  Prepayments to suppliers                         (5,426,601)   (8,750,609)
  Accounts payable                                  3,112,002     1,073,204
  Other payables and accrued expenses              (1,361,439)      710,264
  Deposits from customers                             (92,856)      123,582
  Taxes payable                                     1,078,604     4,234,408
                                                ------------- -------------
  Net cash used in operating activities            (6,122,253)   (2,800,257)
                                                ------------- -------------

CASH FLOWS FROM INVESTING ACTIVITIES:
Payments of long-term prepayments                    (343,960)     (357,226)
Refund of long-term prepayments                       475,560
Loans to third parties                             (1,941,248)   (2,885,501)
Collection of loans to third parties                  802,270    11,054,921
Purchases of property, plant and equipment           (157,782)      (58,560)
Purchases of intangible assets                                      (46,496)
Payments on construction-in-progress                 (182,774)   (7,316,494)
                                                ------------- -------------
Net cash (used in) provided by investing
 activities                                        (1,347,934)      390,644
                                                ------------- -------------

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from short-term loans                      4,503,728     3,277,016
Repayment of short-term loans                      (2,726,544)   (3,043,340)
Proceeds from long-term loan                        1,266,400
Repayment of government grants                       (317,040)
Due to related parties                                331,158         4,960
                                                ------------- -------------
Net cash provided by financing activities           3,057,702       238,636
                                                ------------- -------------

EFFECT OF EXCHANGE RATE CHANGES ON CASH                32,049        66,298
                                                ------------- -------------

DECREASE IN CASH                                   (4,380,436)   (2,104,679)

CASH, beginning of period                           7,048,968     5,887,831
                                                ------------- -------------

CASH, end of period                             $   2,668,532 $   3,783,152
                                                ============= =============

SUPPLEMENTAL DISCLOSURE OF CASH FLOW
 INFORMATION:
Cash paid for interest                          $     508,667 $     266,797
                                                ============= =============
Cash paid for income taxes                      $     971,784 $   1,271,193
                                                ============= =============
Non-cash investing and financing activities
Long-term prepayments transferred to
 construction-in-progress                       $     832,230 $   5,497,461
                                                ============= =============
Long-term prepayments transferred to plant and
 equipment                                      $                 4,727,364
                                                ============= =============
Construction-in-progress transferred to
 property, plant and equipment                  $   1,128,662 $
                                                ============= =============
Share issued to settle payables to related
 parties                                        $     199,239 $
                                                ============= =============



   SKYSTAR BIO-PHARMACEUTICAL COMPANY AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY
                       (Unaudited)



                             Common stock
                          ------------------
                                               Paid-in
                            Shares    Amount   capital
                          ---------- ------- -----------
BALANCE, December 31,
 2011                      7,161,919 $ 7,162 $35,784,378

Share issued under 2010
 stock incentive plan        442,881     443   1,236,707
Foreign currency
 translation
Net income
                          ---------- ------- -----------

BALANCE, September 30,
 2012                      7,604,800 $ 7,605 $37,021,085
                          ========== ======= ===========




                             Retained earnings
                         -------------------------


                                                    Accumulated
                                                       other
                          Statutory                comprehensive
                           reserves   Unrestricted     income       Total
                         ----------- ------------- ------------- -----------
BALANCE, December 31,
 2011                    $ 5,708,135 $  38,492,031 $   8,111,107 $88,102,813

Share issued under 2010
 stock incentive plan                                              1,237,150
Foreign currency
 translation                                             484,203     484,203
Net income                               6,334,874                 6,334,874
                         ----------- ------------- ------------- -----------

BALANCE, September 30,
 2012                    $ 5,708,135 $  44,826,905 $   8,595,310 $96,159,040
                         =========== ============= ============= ===========


Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward-looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the progress of new product development. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the Company's ability to receive timely certification and related government approvals, its ability to increase production at its existing and future facilities, its ability to maintain and meet forecast production and other performance parameters, effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. More information about some of these risks and uncertainties may be found in the reports filed with the Securities and Exchange Commission by the Company. The Company operates in a highly competitive and changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason. Additional risks that could affect our future operating results are more fully described in our U.S. Securities and Exchange Commission filings, including the Company's most recently filed Quarterly Report for the quarter ended September 30, 2012 and other subsequent filings. These filings are available at www.sec.gov.

Contacts:
Grayling Investor Relations
Christopher Chu
(646) 284-9426
Email Contact

Skystar Bio-Pharmaceutical Company
Scott Cramer Director
Director Corporate Development and U.S. Representative
(407) 645-4433

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
"We're a cybersecurity firm that specializes in engineering security solutions both at the software and hardware level. Security cannot be an after-the-fact afterthought, which is what it's become," stated Richard Blech, Chief Executive Officer at Secure Channels, in this SYS-CON.tv interview at @ThingsExpo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Most companies are adopting or evaluating container technology - Docker in particular - to speed up application deployment, drive down cost, ease management and make application delivery more flexible overall. As with most new architectures, this dream takes a lot of work to become a reality. Even when you do get your application componentized enough and packaged properly, there are still challenges for DevOps teams to making the shift to continuous delivery and achieving that reduction in cost ...
Enterprise architects are increasingly adopting multi-cloud strategies as they seek to utilize existing data center assets, leverage the advantages of cloud computing and avoid cloud vendor lock-in. This requires a globally aware traffic management strategy that can monitor infrastructure health across data centers and end-user experience globally, while responding to control changes and system specification at the speed of today’s DevOps teams. In his session at 20th Cloud Expo, Josh Gray, Chie...
To get the most out of their data, successful companies are not focusing on queries and data lakes, they are actively integrating analytics into their operations with a data-first application development approach. Real-time adjustments to improve revenues, reduce costs, or mitigate risk rely on applications that minimize latency on a variety of data sources. Jack Norris reviews best practices to show how companies develop, deploy, and dynamically update these applications and how this data-first...
Intelligent Automation is now one of the key business imperatives for CIOs and CISOs impacting all areas of business today. In his session at 21st Cloud Expo, Brian Boeggeman, VP Alliances & Partnerships at Ayehu, will talk about how business value is created and delivered through intelligent automation to today’s enterprises. The open ecosystem platform approach toward Intelligent Automation that Ayehu delivers to the market is core to enabling the creation of the self-driving enterprise.
"At the keynote this morning we spoke about the value proposition of Nutanix, of having a DevOps culture and a mindset, and the business outcomes of achieving agility and scale, which everybody here is trying to accomplish," noted Mark Lavi, DevOps Solution Architect at Nutanix, in this SYS-CON.tv interview at @DevOpsSummit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"We're here to tell the world about our cloud-scale infrastructure that we have at Juniper combined with the world-class security that we put into the cloud," explained Lisa Guess, VP of Systems Engineering at Juniper Networks, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
Historically, some banking activities such as trading have been relying heavily on analytics and cutting edge algorithmic tools. The coming of age of powerful data analytics solutions combined with the development of intelligent algorithms have created new opportunities for financial institutions. In his session at 20th Cloud Expo, Sebastien Meunier, Head of Digital for North America at Chappuis Halder & Co., discussed how these tools can be leveraged to develop a lasting competitive advantage ...
In his session at 20th Cloud Expo, Mike Johnston, an infrastructure engineer at Supergiant.io, discussed how to use Kubernetes to set up a SaaS infrastructure for your business. Mike Johnston is an infrastructure engineer at Supergiant.io with over 12 years of experience designing, deploying, and maintaining server and workstation infrastructure at all scales. He has experience with brick and mortar data centers as well as cloud providers like Digital Ocean, Amazon Web Services, and Rackspace. H...
The question before companies today is not whether to become intelligent, it’s a question of how and how fast. The key is to adopt and deploy an intelligent application strategy while simultaneously preparing to scale that intelligence. In her session at 21st Cloud Expo, Sangeeta Chakraborty, Chief Customer Officer at Ayasdi, will provide a tactical framework to become a truly intelligent enterprise, including how to identify the right applications for AI, how to build a Center of Excellence to ...
You know you need the cloud, but you’re hesitant to simply dump everything at Amazon since you know that not all workloads are suitable for cloud. You know that you want the kind of ease of use and scalability that you get with public cloud, but your applications are architected in a way that makes the public cloud a non-starter. You’re looking at private cloud solutions based on hyperconverged infrastructure, but you’re concerned with the limits inherent in those technologies.
SYS-CON Events announced today that Massive Networks will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Massive Networks mission is simple. To help your business operate seamlessly with fast, reliable, and secure internet and network solutions. Improve your customer's experience with outstanding connections to your cloud.
DevOps is under attack because developers don’t want to mess with infrastructure. They will happily own their code into production, but want to use platforms instead of raw automation. That’s changing the landscape that we understand as DevOps with both architecture concepts (CloudNative) and process redefinition (SRE). Rob Hirschfeld’s recent work in Kubernetes operations has led to the conclusion that containers and related platforms have changed the way we should be thinking about DevOps and...
As businesses adopt functionalities in cloud computing, it’s imperative that IT operations consistently ensure cloud systems work correctly – all of the time, and to their best capabilities. In his session at @BigDataExpo, Bernd Harzog, CEO and founder of OpsDataStore, presented an industry answer to the common question, “Are you running IT operations as efficiently and as cost effectively as you need to?” He then expounded on the industry issues he frequently came up against as an analyst, and ...
All organizations that did not originate this moment have a pre-existing culture as well as legacy technology and processes that can be more or less amenable to DevOps implementation. That organizational culture is influenced by the personalities and management styles of Executive Management, the wider culture in which the organization is situated, and the personalities of key team members at all levels of the organization. This culture and entrenched interests usually throw a wrench in the work...